-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

Benzinga·06/15/2026 13:47:45
Listen to the news
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $12 price target.